# Connect Biopharma Holdings Limited (CNTB) · Edgar & Edgarette company card

> Connect Biopharma Holdings Limited (CNTB) saw revenue fall 99.8% in FY2025 to $0 million, operating margin -90741% against a -3.8% median for pharmaceutical preparations, equity 74.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1835268 · fiscal year ended 2025-12-31 · 3 audited years read · [page](https://www.pops4.com/boards/company/CNTB) · [JSON](https://www.pops4.com/boards/company/CNTB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $64,000 |
| Revenue growth, 1 year | -99.8% |
| Revenue growth per year | — |
| Operating margin | -90740.6% (prior year -86.2%) |
| Net margin | -86687.5% |
| Operating cash flow | −$51M |
| Capital spending | $434,000 |
| Free cash flow | −$52M |
| Cash | $38M |
| Long-term debt | — |
| Total assets | $56M |
| Total equity | $42M |
| Equity ÷ assets | 74.9% |
| Return on equity | -132.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -22.77 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$51.2M in FY2025); operating loss: a margin of -90740.6% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $64K (FY2025). Experience: revenue down 99.8% on the year; operating margin -90740.6%, down from -86.2%. Soundness: equity 74.9% of assets, return on equity -132.2%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -90740.6% against a -3.8% median; growth -99.8% against 13.7%.

Range logged 2026-09-20, receipt a55152464a6549d3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-12-23 ([filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000061/0001835268-25-000061-index.htm))

## Recent filings

- 8-K · filed 2026-09-30 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/0001835268-26-000038-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000034/0001835268-26-000034-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000028/0001835268-26-000028-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/0001835268-26-000027-index.htm)
- 10-Q · filed 2026-05-12 · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000020/0001835268-26-000020-index.htm)
- 8-K · filed 2026-05-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001835268.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1835268

## Cite

POPS4, Edgar & Edgarette: Connect Biopharma Holdings Limited (CNTB) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/CNTB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.